Sorrento Therapeutics

Sorrento Therapeutics financials

Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.

CreditSafe score

?

Score changed on Feb 06, 2023

Premium Content

Financial statements

USD	FY, 2011	FY, 2012	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017	FY, 2018	FY, 2019	FY, 2020	FY, 2021
Revenue	529.2K	583.8K	460.1K	3.8M	4.6M	8.2M	151.9M	21.2M	31.4M	40.0M	52.9M
Revenue growth, %				731.3%	20.0%	77.6%
Cost of goods sold			4.4K	2.0M	2.0M	811.0K	3.9M	7.1M
Gross profit			455.7K	1.8M	2.6M	7.3M	147.9M	14.1M
Gross profit margin, %			99.0%	46.6%	57.5%	90.1%	97.4%	66.7%
General and administrative expense	1.2M	1.6M	6.3M	10.0M	20.1M	24.2M	38.3M	63.6M	103.6M	116.2M	196.9M
Operating expense total	3.8M	5.4M	22.1M	36.5M	76.6M	104.1M	122.6M	164.6M	210.4M	227.5M
EBIT	(3.2M)	(4.9M)	(21.7M)	(34.7M)	(74.0M)	(96.8M)	25.3M	(150.4M)	(259.4M)	(244.5M)	(401.5M)
EBIT margin, %	-612.7%	-831.2%	-4708.9%	-908.3%	-1612.3%	-1187.2%	16.7%	-709.8%	-825.3%	-611.5%
Investment income					(4.0M)	435.0K	(40.2M)	(5.0M)	(3.9M)	(5.8M)	(126.0K)
Interest income	6.0K	7.3K	9.6K	12.0K	24.0K	272.0K	241.0K	921.0K	1.1M	24.0K
Pre tax profit				(36.4M)	(13.8M)	(64.8M)	15.3M	(213.8M)	(359.6M)	(310.6M)	(462.5M)
Income tax expense				(1.7M)	36.3M	(896.0K)	(36.0M)	(6.3M)	(473.0K)	(2.0M)	(33.5M)
Net Income	(3.2M)	(4.8M)	(21.9M)	(34.7M)	(45.8M)	(60.9M)	9.1M	(203.5M)	(363.0M)	(314.4M)	(429.1M)

Footer menu

Products

Solutions

Resources

Company

© Craft.co 2023

Share price data provided by IEX

Company directory

Search directory